Skip to main content

Why this East Bay drug maker's stock price nearly doubled last year

The aesthetics market dominated by Botox is the billion-dollar target of Revance Therapeutics. But the Newark company's head-to-toe strategy includes therapeutic uses.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.